**SDC 1. Clinical Features of Influenza A and B Virus Infection in Immunocompromised Patients.**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Patient | Age (years) | Influenza subtype | Day(s) of sample collection¤ | Duration of viral shedding(days)§ | Duration of symptoms (days) | Antiviral therapy | Duration of antiviral therapy (days)\* | Cancer diagnosis/status | Chemotherapy phase | ANCϕ | ALCϕ |
| 1 | 5 | A (H3N2) | -1, 16 | 37 | 44 | Oseltamivir | 5 + 5 (5) | ALL/remission | Continuation | 500 | 256 |
| 2 | 6 | A (H3N2) | 5, 8 | 14 | 18 | Oseltamivir | 5 | ALL/ remission | Consolidation | 300 | 192 |
| 3 | 13 | A (H3N2) | -1, 25, 39, 97 | 124 | Unknown | Oseltamivir | 5 + 5 + 5  (22, 68) | AML/not in remission | HSCT | 100 | NA |
| 4 | 20 | A (H3N2) | 0 | 35 | 35 | Oseltamivir | 5 | AML/remission | HSCT | 9,179‡ | 274 |
| 5 | 1 | A (H3N2) | 0, 6 | 6 | 37 | Oseltamivir +  Amantadine | 1 (Oseltamivir) +  5 (Amantadine) | ST/remission | HSCT | 8,800 | 968 |
| 6 | 1 | A (H3N2) | 2, 4, 7 | 21 | 21 | Oseltamivir | 1 + 7 (8) | ALL/ remission | Consolidation | 900 | 336 |
| 7 | 18 | A (H3N2) | -1 | Unknown | 35 | Oseltamivir | 5 | Acute T-cell LGL leukemia/not in remission | NA | 2,100 | 3,534 |
| 8 | 17 | A (H3N2) | -1, 15, 26 | Unknown | 55 | Oseltamivir | 5 | MDS/remission | HSCT | 1,600 | 396 |
| 9 | 23 | A (H1N1) | -1 | 20 | 34 | Oseltamivir | 5 | NHL/remission | Continuation | 12,400 | 268 |
| 10 | 2 | B | -3 | 21 | 33 | Oseltamivir | 5 + 5 + 5 (2, 7) | ALL/not in remission | Induction | 100 | 957 |
| 11 | 3 | B | -2, 5 | 11 | 11 | Oseltamivir | 5 | ALL/not in remission | Induction | 100 | 612 |
| 12 | 7 | B | 0, 25 | 25 | 33 | Oseltamivir | 5 + 10 (15) | ALL/remission | Continuation | 1,300 | 260 |

¤ With respect to the first day of antiviral therapy.

§ Detected by culture, PCR or DFA.

\* Numbers in parentheses represent the interval between courses (days).

Φ Cells/mm3.

‡ Receiving granulocyte colony stimulator factor (GCSF).

ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; HSCT, hematopoietic stem cell transplant; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; ST, solid tumor; acute T-cell LGL leukemia, acute T-cell large granular lymphocyte leukemia; NA, not applicable.